Eric Jacobson - Concepedia

Author

Eric Jacobson

Synta Pharmaceuticals (United States)ORCID

Also Known As

E JACOBSON, E Jacobson, E. Jacobson, E.W. Jacobson, Eric Jacobson, Eric W Jacobson, Eric W. Jacobson, Erica Elizabeth Jacobson

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Synta Pharmaceuticals (United States)GlaxoSmithKline (United States)GlaxoSmithKline (United Kingdom)Tris Pharma (United States)University of Massachusetts Chan Medical School

About

Eric Jacobson is an author at Synta Pharmaceuticals (United States) specializing in medicine, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	749
2	Health Sciences	1	1	423
3	Nursing	1	1	21
4	Anesthesia	1	1	28
5	Family Medicine	1	1	21

Eric Jacobson

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases—Safety, Pharmacokinetics, and Pharmacodynamics Lynne Howells, D.P. Berry, P.J. Elliott, Cancer Prevention Research Chemoprevention StrategySrt501 WarrantsOncologyHepatobiliary TumorHepatotoxicity	2011	423
Modulation of CCR2 in rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled clinical trial Clarissa E. Vergunst, Daniëlle M. Gerlag, Luba Lopatinskaya, Arthritis & Rheumatism	2008	232
Gamma‐linolenic acid treatment of rheumatoid arthritis. A randomized, placebo‐controlled trial Robert B. Zurier, Ronald G. Rossetti, Eric Jacobson, Arthritis & Rheumatism	1996	201
Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma Steven O’Day, René González, David H. Lawson, Journal of Clinical Oncology	2009	196
Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21 Douglas C. Waite, Eric Jacobson, Francis A. Ennis, Vaccine Therapeutic Drug MonitoringMedicinal ChemistryMedicineDifferent FormulationsPharmacotherapy	2001	130
Pharmacokinetics and tolerability of <scp>SRT</scp>2104, a first‐in‐class small molecule activator of <scp>SIRT</scp>1, after single and repeated oral administration in man Ethan Hoffmann, J. Wald, Siva Lavu, British Journal of Clinical Pharmacology	2012	124
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers Vincenzo Libri, Andrew Brown, Giulio Gambarota, PLoS ONE	2012	123
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease Bruce E. Sands, Eric Jacobson, Thomas Sylwestrowicz, Inflammatory Bowel Diseases	2009	108
A phase 1/2A Trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohnʼs disease Robert Burakoff, Charles F. Barish, Dennis Riff, Inflammatory Bowel Diseases	2006	107
A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis James G. Krueger, Mayte Suárez‐Fariñas, Inna Cueto, PLoS ONE	2015	99

Page 1